Volume dana dhuwit perusahaan Co-Diagnostics, Inc. (CODX)

Co-Diagnostics, Inc. (CODX) generates stable revenue based on the sale of PCR systems and the subsequent sale of high-cost reagents. Free cash flow levels confirm this financial stability, where 0.00 determines the latest valuation metric. The company is currently expanding government partnerships to implement diagnostic platforms while simultaneously updating its Co-Primers test line for the agricultural sector and infection control.
Rincian analitis lan laporan data perusahaan Co-Diagnostics Corp (CODX)

This indicator captures the current level of liquid assets, serving as a fundamental safeguard against market volatility and ensuring operational autonomy. By analyzing the volume of operating cash, investors assess the ability of Co-Diagnostics, Inc. (CODX) to maintain premium pricing for Co-Primers PCR tests, where high diagnostic accuracy allows the company to accumulate significant capital regardless of external macroeconomic shocks.